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Abstract
Hepatocellular carcinoma (HCC) is one of the most 
common malignancies leading to high mortality 
rates in the general population and the sixth most 
common cancer worldwide. HCC is characterized by 
deregulation of multiple genes and signalling pathways. 
These genetic effects can involve both protein coding 
genes as well as non-coding RNA genes. Long non-
coding RNAs (lncRNAs) are transcripts longer than 
200 nt, constituting a subpopulation of ncRNAs. Their 
biological effects are not well understood compared 
to small non-coding RNA (microRNAs), but they have 
been recently recognized to exert a crucial role in 
the regulation of gene expression and modulation 
of signalling pathways. Notably, several studies 
indicated that lncRNAs contribute to the pathogenesis 
and progression of HCC. Investigating the molecular 
mechanisms underlying lncRNAs expression opens 
potential applications in diagnosis and treatment of liver 
disease. This editorial provides three examples (MALAT-1 
metastasis associated lung adenocarcinoma transcript, 
HULC highly upregulated in liver cancer and HOTAIR 
HOX transcript antisense intergenic RNA) of well-known 
lncRNAs upregulated in HCC, whose mechanisms of 
action are known, and for which therapeutic applications 
are delineated. Targeting of lncRNAs using several 
approaches (siRNA-mediated silencing or changing their 
secondary structure) offers new possibility to treat HCC. 
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Core tip: The long non-coding RNAs discovery opens a 
meaningful collision with epigenetics and reveals new 
roles of RNA in most of cellular processes. This focus 
explores the functional potentiality of RNAs in the liver 
in light of most recent knowledge.
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TEXT
Recent advances in massive parallel sequencing, 
especially RNA sequencing (RNAseq), reveal that at 
least 90% of the human genome is transcribed into 
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non-coding RNAs (ncRNAs), while surprisingly less 
than 2% encodes protein-coding genes. Besides the 
different types of ncRNAs smaller than 200 nucleotides, 
such as microRNAs (miRNAs) or PIWI-interacting RNAs, 
a large proportion of human transcriptome results in 
RNAs that are longer than 200 nucleotides. Speaking 
in terms of numbers, this means that about 9000 
small ncRNAs and about 32000 long ncRNAs (lncRNAs) 
have been identified vs 21000 protein coding genes[1]. 
The importance of the lncRNAs has been proven in 
recent years, as multiple research groups functionally 
characterized the relevant lncRNAs role in development, 
epigenetics, cell differentiation and cancer[2]. Basically, 
lncRNAs can be defined as often polyadenylated RNA, 
lacking clear open reading frames (ORFs)[2]. The 
sequence length of this family gives them the ability to 
have complex secondary structures and to turn inward 
revealing a tertiary structure[3]. De novo discovery and 
expression analysis of lncRNAs by RNAseq allowed 
them to be classified along the cell lines, highlighting 
that lncRNAs expression is strikingly tissue-specific 
compared with coding genes. Batista et al[4] also 
underline the “address code”, both spatial and temporal, 
of the lncRNAs as key components in cell fate during 
the development. The repertoire of the functions of 
lncRNAs seems to be getting more and more increasing 
and spans between transcription and regulation of 
messenger RNA (mRNA) processing or translation. They 
can act in cis or in trans and the cells can use them to 
modulate gene expression as well as to bind miRNAs, 
thereby behaving like a sponge in order to protect the 
mRNAs target from degradation (ceRNAs)[1]. 
This editorial focuses on three well-known lncRNAs in 
the liver and on their potential application as therapeutic 
targets: metastasis associated lung adenocarcinoma 
transcript 1 (MALAT-1), highly upregulated in liver 
cancer (HULC) and HOX transcript antisense intergenic 
RNA (HOTAIR). 
LncRNA MALAT-1 is frequently upregulated in both 
liver cancer cell lines and hepatocellular carcinoma 
(HCC) tissue samples; moreover analysis of clinical data 
demonstrated that its level is an independent prognostic 
factor for HCC recurrence after liver transplantation[5], 
potentially acting as a novel biomarker. MALAT-1 is 
involved in mRNA splicing[6] and may play an essential 
role in cell cycle regulation[7]. Recent and encouraging 
studies indicate that antisense oligonucleotides specific 
to match MALAT-1 disrupt its function, attenuating the 
corresponding phenotype in cancer cell[8]. A treatment 
targeting MALAT-1 may be a significant approach in 
patients following liver transplantation.  
One example of ceRNAs class, which has been well 
characterized in the liver, is HULC. The lncRNA HULC is 
upregulated in HCC and was found to contain mir-372 
binding sites. HULC overexpression can reduce mir-372 
level, leading to an induction of PRKACB, which in turn 
induces CREB phosphorylation[9]. Phosphorylated CREB 
protein binds to a cAMP response element region, and 
is then bound to by CBP, which coactivates it, leading to 
the acetylation of the histone tail and maintaining the 
open configuration of the chromatin. This regulatory 
circuitry provides an example of gene reprogramming 
during tumorigenesis. Interestingly, a recent paper 
showed that hepatitis B virus X protein (HBx) positively 
correlated with HULC in clinical HCC tissues. Moreover, 
HBx also activated the HULC promoter in HepG2 
cell lines[10]. Liu et al[11] demonstrated that a single 
nucleotide polymorphism at HULC was associated with 
decreased sponge activity and decreased HCC risk. It 
suggests that therapeutic agents that compete with 
miRNA binding may be useful to treat HCC patients[11]. 
The third well-known lncRNA is HOTAIR, which 
is always overexpressed in HCC and liver cancer cell 
lines. HOTAIR increases PCR2 recruitment to the 
genomic loci and in this way, it mediates the epigenetic 
repression of PCR2 target genes, modifying the profile 
of positive (H3K4me3) or negative (H3K27me3) 
chromatin marks[12]. Notably, this kind of lncRNA fits 
into the universe of the chromatin world by changing its 
structure. An increasing number of chromatin-associated 
proteins have been implicated in RNA binding, support-
ing the idea that epigenetic effects are RNA-dependent. 
Altering the secondary structure of HOTAIR may 
prevent to embed PCR2 and the consequent aberrant 
epigenome[13]. 
All together, these evidences suggest that lncRNAs 
are strongly associated with liver cancer and they have 
real potential roles as biomarkers for disease diagnosis, 
prognosis, or therapeutic response as well as direct 
targets for therapeutic intervention. 
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